SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Price, Forecast & Analysis
NASDAQ:SUPN • US8684591089
SUPN Key Statistics, Chart & Performance
The current stock price of SUPN is 50.65 USD. In the past month the price decreased by -0.21%. In the past year, price increased by 31.27%.
SUPN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SUPN. When comparing the yearly performance of all stocks, SUPN is one of the better performing stocks in the market, outperforming 80.84% of all stocks.
SUPN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SUPN. SUPN has only an average score on both its financial health and profitability.
SUPN Financial Highlights
Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 3.1. The EPS increased by 0.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| Debt/Equity | 0 |
SUPN Forecast & Estimates
12 analysts have analysed SUPN and the average price target is 62.56 USD. This implies a price increase of 23.51% is expected in the next year compared to the current price of 50.65.
For the next year, analysts expect an EPS growth of -9.24% and a revenue growth 9.18% for SUPN
SUPN Ownership
SUPN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.01 | 959.759B | ||
| JNJ | JOHNSON & JOHNSON | 20.96 | 580.304B | ||
| MRK | MERCK & CO. INC. | 22.35 | 296.13B | ||
| PFE | PFIZER INC | 9.2 | 157.665B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.94 | 122.002B | ||
| ZTS | ZOETIS INC | 19.03 | 56.704B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.64 | 25.543B | ||
| VTRS | VIATRIS INC | 6.3 | 18.578B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.32 | 12.774B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224 | 9.387B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SUPN
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Company Info
SUPERNUS PHARMACEUTICALS INC
9715 Key West Avenue
Rockville MARYLAND 20850 US
CEO: JACK A. KHATTAR
Employees: 674
Phone: 13018382500
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you describe the business of SUPERNUS PHARMACEUTICALS INC?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
What is the current price of SUPN stock?
The current stock price of SUPN is 50.65 USD. The price decreased by -1.34% in the last trading session.
Does SUPN stock pay dividends?
SUPN does not pay a dividend.
How is the ChartMill rating for SUPERNUS PHARMACEUTICALS INC?
SUPN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of SUPERNUS PHARMACEUTICALS INC (SUPN)?
The PE ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 16.34. This is based on the reported non-GAAP earnings per share of 3.1 and the current share price of 50.65 USD.
Should I buy SUPN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SUPN.
Who owns SUPERNUS PHARMACEUTICALS INC?
You can find the ownership structure of SUPERNUS PHARMACEUTICALS INC (SUPN) on the Ownership tab.